Drug Trial Radar · NCT04370704
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
61
Actual
Start
Jul 27, 2020
Primary completion
Aug 25, 2025
Study completion Aug 25, 2025
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- May 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.
Conditions
- Melanoma
Interventions
INCAGN02385Drug
INCAGN02385 administered intravenously
INCAGN02390Drug
INCAGN02390 administered intravenously
INCMGA00012.Drug
INCMGA00012 administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)Time frame: up to 1148 days
- Phase 1: Number of Participants With Any ≥Grade 3 TEAETime frame: up to 1148 days
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
The Angeles Clinic and Research Institute
Los Angeles, California
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida
H Lee Moffitt Cancer Center and Research
Tampa, Florida
University of Iowa
Iowa City, Iowa
Cancer Center For Blood Disorders A Division of American Oncology Partners P.A
Bethesda, Maryland
Washington University
St Louis, Missouri
John Theurer Cancer Center, Hackensack University Medical Center
Hackensack, New Jersey
Nyu Langone Laura and Isaac Perlmutter Cancer Center
New York, New York
Carolina Bio Oncology
Huntersville, North Carolina
Penn State Hershey Cancer Institute
Hershey, Pennsylvania
Hillman Cancer Center
Pittsburgh, Pennsylvania
University of Washington-Seattle Cancer Care Alliance
Seattle, Washington
Melanoma Institute Australia
Wollstonecraft, New South Wales, Australia
Greenslopes Private Hospital
Brisbane, Queensland, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
One Clinical Research
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.